Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

BACKGROUND: Bezlotoxumab is approved for prevention of recurrence of Clostridioides difficile infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and validation of trial results in the real world are limited...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Hengel, Richard L, Ritter, Timothy E, Nathan, Ramesh V, Van Anglen, Lucinda J, Schroeder, Claudia P, Dillon, Ryan J, Marcella, Stephen W, Garey, Kevin W
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Major Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7186524/
https://ncbi.nlm.nih.gov/pubmed/32363211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa097
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados